Company intelligence / Profile preview

Sumitomo Pharma

Osaka, Osaka, Japansumitomo-pharma.com ↗
Ownership
Public · 4506
Employees
~4767
Development stage
Commercial
01

Overview

Sumitomo Pharma has several commercialized drugs in psychiatry/neuroscience and urology/women's health. It continues to advance a robust pipeline with late-stage assets in cell therapy for Parkinson’s disease and retinal disorders. The company faces financial headwinds post-patent expiry of key products but remains active in global R&D with a strategic pivot toward innovation-driven growth.

Therapeutic areas
OncologyRare DiseasesPsychiatryNephrologyWomen's Health
Modalities
Small molecule drugsSynthetic peptidesInduced pluripotent stem cells (iPSC)/cell therapyTherapeutic vaccines
Industry
Biotech
02

Drug pipeline

59 assets

zonisamide

Approved

58 more assets in the full pipeline.

03

Partnerships

Strategic alliance with Roivant Sciences led to creation of “Sumitovant Biopharma” holding Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics among others.Other partnerships exist with academic institutions and biotechs.
04

Financials

Market cap
$5.2B
Total revenue
$2.9B
Enterprise value
$5.6B

Beyond the preview

Go deeper on Sumitomo Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sumitomo Pharma.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call